Allopurinol

Generic Name: Allopurinol

Brand Names: Aloprim, Zyloprim

Drug Type: Small Molecule

Chemical Formula: C_₅H_₄N_₄O

CAS Number: 315-30-0

Unique Ingredient Identifier: 63CZ7GJN5I

Background: Gout is a disease that occurs by the deposition of monosodium urate crystals (MSU) in body tissues, especially around joints . This disease has been well-documented in historical medical records and appears in the biographies of several prominent, historically recognized individuals .
...

Indication: Allopurinol is indicated in :

1) the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy).
...

Associated Conditions: Hyperuricemia, Primary Gout, Recurrent calcium oxalate calculi, Secondary gout, Calcium oxalate calculi Renal Calculi

Associated Therapies: -

Clinical Trials

Uric Acid in Essential Hypertension in Children

Phase 2

Completed

Conditions: Essential Hypertension

Interventions: Drug: Placebo
Drug: Allopurinol

First Posted Date: 2006-02-07

Last Posted Date: 2017-09-14

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 30

Registration Number: NCT00288184

Locations: 🇺🇸
Texas Children's Hospital, Houston, Texas, United States

Intravenous Allopurinol to Improve Heart Function in Individuals With Dilated Cardiomyopathy

Phase 1

Withdrawn

Conditions: Cardiovascular Diseases
Cardiomyopathy, Dilated
Heart Diseases
Heart Failure, Congestive

Interventions: Drug: Allopurinol
Drug: Dobutamine

First Posted Date: 2006-01-24

Last Posted Date: 2013-06-19

Lead Sponsor: University of Pennsylvania

Registration Number: NCT00281255

Locations: 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Uric Acid and Hypertension in African Americans

Phase 3

Completed

Conditions: Cardiovascular Diseases
Heart Diseases
Hypertension

Interventions: Drug: Placebo
Drug: Allopurinol
Drug: Chlorthalidone
Drug: Potassium chloride

First Posted Date: 2005-10-19

Last Posted Date: 2013-07-26

Lead Sponsor: University of Florida

Target Recruit Count: 150

Registration Number: NCT00241839

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States

Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome

Phase 3

Completed

Conditions: Tumor Lysis Syndrome
Cancer
Hyperuricemia

Interventions: Drug: Rasburicase (SR29142)
Drug: Allopurinol

First Posted Date: 2005-09-30

Last Posted Date: 2010-01-12

Lead Sponsor: Sanofi

Target Recruit Count: 280

Registration Number: NCT00230178

Locations: 🇺🇸
University of Florida Health Science Center at Jacksonville, Jacksonville, Florida, United States
🇺🇸
New York Methodist Hospital, Brooklyn, New York, United States
🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States

and more 12 locations

Vascular Pathophysiology in Obstructive Sleep Apnea

Not Applicable

Withdrawn

Conditions: Obstructive Sleep Apnea

First Posted Date: 2005-09-21

Last Posted Date: 2015-10-08

Lead Sponsor: University of Wisconsin, Madison

Registration Number: NCT00214084

Locations: 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States

Treatment of Hyperuricemia With Rasburicase in Patients With Acute Lymphoblastic Leukemia or High Grade Lymphoma

Phase 3

Completed

Conditions: Adult Acute Lymphocytic Leukemia
High-grade Lymphoma

Interventions: Drug: Allopurinol
Drug: Rasburicase

First Posted Date: 2005-09-20

Last Posted Date: 2023-03-17

Lead Sponsor: Goethe University

Target Recruit Count: 80

Registration Number: NCT00199043

Locations: 🇩🇪
University Hospital, Medical Dept. II, Frankfurt, Germany

Intravenous Allopurinol in Heart Failure

Phase 2

Completed

Conditions: Congestive Heart Failure

Interventions: Drug: Placebo
Drug: Allopurinol

First Posted Date: 2005-09-16

Last Posted Date: 2017-05-30

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 18

Registration Number: NCT00181155

Locations: 🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States

Phase 3, Febuxostat, Allopurinol and Placebo-Controlled Study in Gout Subjects.

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Placebo
Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2005-09-15

Last Posted Date: 2012-02-02

Lead Sponsor: Takeda

Target Recruit Count: 1072

Registration Number: NCT00174915

Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010

Phase 3

Completed

Conditions: Gout

Interventions: Drug: Febuxostat
Drug: Allopurinol

First Posted Date: 2005-09-15

Last Posted Date: 2010-07-27

Lead Sponsor: Takeda

Target Recruit Count: 1086

Registration Number: NCT00175019

S0333 Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin
Drug: dexamethasone
Drug: doxorubicin
Drug: leucovorin
Drug: mercaptopurine
Drug: methotrexate
Drug: mitoxantrone
Drug: Asparaginase
Drug: prednisone
Drug: thioguanine
Drug: vincristine
Radiation: radiation therapy
Drug: allopurinol
Drug: bactrim

First Posted Date: 2005-05-04

Last Posted Date: 2015-03-25

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 79

Registration Number: NCT00109837

Locations: 🇺🇸
Providence Saint Joseph Medical Center - Burbank, Burbank, California, United States
🇺🇸
Gibbs Regional Cancer Center at Spartanburg Regional Medical Center, Spartanburg, South Carolina, United States
🇺🇸
Minor and James Medical, PLLC, Seattle, Washington, United States

and more 75 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy